569250-U
Discovery® HS C18 (3 µm) HPLC Columns
L × I.D. 5 cm × 4.6 mm, HPLC Column
别名:
Discovery RP18 HPLC Column
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
5 cm × 4.6 mm
Particle size:
3 μm
Matrix active group:
C18 (RP18), C18 (octadecyl) phase
Pore size:
120 Å
Matrix:
silica gel, high purity, spherical particle platform, fully porous particle
产品名称
Discovery® HS C18 高效液相色谱柱, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
material
stainless steel column
Quality Segment
agency
suitable for USP L1
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
20% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
5 cm × 4.6 mm
surface area
300 m2/g
surface coverage
3.2 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical particle platform, fully porous particle
matrix active group
C18 (RP18), C18 (octadecyl) phase
particle size
3 μm
pore size
120 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
Application
- A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).
- Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).
- Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).
Features and Benefits
- 稳定性好、低流失，适用于 LC-MS 分析
- 提供有适用于分析型到制备型的各种规格
- 稳定性好，以确保柱与柱和批与批之间之间优良的重现性
- 更强的疏水性能够更好地分离难分析化合物
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery® HS C18 高效液相色谱柱